Home > Boards > US OTC > Biotechs > Oxford BioMedica PLC (OXBDF)

First two patients dosed in SUNRISE-PD phase 2

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
georgejjl Member Profile
 
Followed By 79
Posts 11,290
Boards Moderated 0
Alias Born 04/08/04
160x600 placeholder
georgejjl   Tuesday, 02/12/19 08:05:01 PM
Re: None
Post # of 750 
Quote:
First two patients dosed in SUNRISE-PD phase 2 trial of AXO-Lenti-PD for Parkinson's disease and initial patient dosed with AXO-AAV-GM2; data from both programs expected in March 2019

Axovant Sciences Ltd. intends to change its name to Axovant Gene Therapies Ltd. and ticker symbol to “AXGT” to reflect its exclusive focus on gene therapies



http://investors.axovant.com/news-releases/news-release-details/axovant-announces-third-fiscal-quarter-2018-financial-results

Good luck and GOD bless,


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist